GSK PLC GLAXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLAXF is a good fit for your portfolio.
News
-
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim — Update
-
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim
-
GSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use
-
GSK Buys Elsie Biotechnologies for Up to $50 Million
-
GSK Down Nearly 9%, on Pace for Largest Percent Decrease Since March 2020 — Data Talk
-
Trending: GSK Shares Tumble on Zantac's Legal Setback
-
GSK Shares Plunge After Delaware Ruling Allowing Jury Trials for Zantac Case — Update
-
GSK Shares Plunge After Delaware Ruling on Zantac
Trading Information
- Previous Close Price
- $20.81
- Day Range
- $20.70–21.61
- 52-Week Range
- $16.69–23.00
- Bid/Ask
- $19.30 / $21.86
- Market Cap
- $88.13 Bil
- Volume/Avg
- 778 / 2,424
Key Statistics
- Price/Earnings (Normalized)
- 10.67
- Price/Sales
- 2.30
- Dividend Yield (Trailing)
- 3.43%
- Dividend Yield (Forward)
- 3.53%
- Total Yield
- 3.44%
Company Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 70,200
- Website
- https://www.gsk.com
Competitors
Valuation
Metric
|
GLAXF
|
MRK
|
PFE
|
---|---|---|---|
Price/Earnings (Normalized) | 10.67 | 60.00 | 19.56 |
Price/Book Value | 5.04 | 8.17 | 1.72 |
Price/Sales | 2.30 | 5.40 | 2.87 |
Price/Cash Flow | 10.43 | 18.99 | 18.45 |
Price/Earnings
GLAXF
MRK
PFE
Financial Strength
Metric
|
GLAXF
|
MRK
|
PFE
|
---|---|---|---|
Quick Ratio | 0.57 | 0.68 | 0.58 |
Current Ratio | 0.87 | 1.25 | 0.91 |
Interest Coverage | 8.94 | 3.97 | 0.74 |
Quick Ratio
GLAXF
MRK
PFE
Profitability
Metric
|
GLAXF
|
MRK
|
PFE
|
---|---|---|---|
Return on Assets (Normalized) | 11.25% | 5.22% | 4.98% |
Return on Equity (Normalized) | 51.21% | 13.56% | 10.90% |
Return on Invested Capital (Normalized) | 22.40% | 8.29% | 7.28% |
Return on Assets
GLAXF
MRK
PFE
Drug Manufacturers - General Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Eli Lilly and Co
LLY
| Pvyxvlkfs | Kykm | $824.3 Bil | |||
Johnson & Johnson
JNJ
| Nlngdgjq | Jwdw | $353.2 Bil | |||
Merck & Co Inc
MRK
| Xqvpldds | Zpx | $333.9 Bil | |||
AbbVie Inc
ABBV
| Nsxrbpr | Cqhgf | $296.1 Bil | |||
AstraZeneca PLC ADR
AZN
| Rpjnmybnx | Nysq | $244.1 Bil | |||
Roche Holding AG ADR
RHHBY
| Slwktbdryw | Bqmt | $219.2 Bil | |||
Novartis AG ADR
NVS
| Xkyfctmn | Lyk | $214.1 Bil | |||
Amgen Inc
AMGN
| Qyprxspzck | Cwvt | $161.3 Bil | |||
Pfizer Inc
PFE
| Msqjfdfll | Xmhj | $156.7 Bil | |||
Sanofi SA ADR
SNY
| Stcxpvs | Nkcfn | $120.9 Bil |